{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:43:15Z","timestamp":1773409395154,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Genetics and Cytogenetics"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.cancergencyto.2008.12.013","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T08:17:31Z","timestamp":1240388251000},"page":"1-9","source":"Crossref","is-referenced-by-count":8,"title":["Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results"],"prefix":"10.1016","volume":"191","author":[{"given":"Milena","family":"Holzerov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Veselovsk\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Urb\u00e1nkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Balc\u00e1rkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0160\u00e1rka","family":"Ro\u017emanov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslava","family":"Voglov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Mu\u017e\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Chroust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Indr\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Jaro\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergencyto.2008.12.013_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000132374","article-title":"Variant Philadelphia translocations in chronic myeloid leukemia","volume":"44","author":"De Braekeleer","year":"1987","journal-title":"Cytogenet Cell Genet"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-4608(94)90083-3","article-title":"Complex translocations of the Ph chromosome and Ph negative CML arise from similar mechanisms, as evidenced by FISH analysis","volume":"78","author":"Calabrese","year":"1994","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib4","first-page":"321a","article-title":"Variant t(9;22) translocation may identify a subgroup of chronic myeloid leukemia patients with poor prognosis","volume":"98","author":"Albano","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-\u03b1 treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib8","first-page":"1134","article-title":"Aberrant cytogenetic evaluation pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-\u03b1","volume":"10","author":"Johansson","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","article-title":"France Intergroupe pour la Leuc\u00e9mie My\u00e9lo\u00efde Chronique. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia","volume":"18","author":"Terre","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib10","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortez","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2004.05215.x","article-title":"Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?","volume":"127","author":"O'Shea","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"17","author":"Schoch","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib14","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood-2003-01-0123","article-title":"Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia","volume":"102","author":"Huntly","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib15","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V98.6.1732","article-title":"Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia","volume":"98","author":"Huntly","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukaemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0165-4608(03)00099-2","article-title":"Complex karyotypes in childhood acute lymphoblastic leukemia: cytogenetic and molecular cytogenetic study of 21 cases","volume":"145","author":"Jarosov\u00e1","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib18","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib19","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib20","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Quintas-Cardama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.leu.2401718","article-title":"Lack of BCR\/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping","volume":"14","author":"Markovic","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib22","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Quintas-Cardama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib23","first-page":"68","article-title":"Detection of trisomy 8 in Philadelphia chromosome-positive CML patients using conventional cytogenetic and interphase fluorescence in situ hybridization techniques and its relation to c-myc involvement","volume":"31","author":"Oudat","year":"2001","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib24","first-page":"1333","article-title":"The effect on imatinib mesylate on patients with Philadelphia chromosome positive chronic myeloid leukemia with secondary chromosomal aberrations","volume":"9","author":"Mohamed","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0165-4608(87)90131-2","article-title":"The karyotype of blastic crisis","volume":"26","author":"Alimena","year":"1987","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.leu.2402848","article-title":"Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate","volume":"17","author":"O'Dwyer","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.2006.06285.x","article-title":"Occurrence of the same chromosome abnormalities in Ph+ and Ph\u2212 cells in chronic myeloid leukemia: evidence of secondary origin of the Ph chromosome?","volume":"135","author":"Donti","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1034\/j.1600-0609.2003.00148.x","article-title":"Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy of imatinib mesylate (STI)","volume":"71","author":"Gozzetti","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cancergencyto.2006.04.012","article-title":"Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors","volume":"170","author":"Lin","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"issue":"Suppl. 1","key":"10.1016\/j.cancergencyto.2008.12.013_bib30","first-page":"467","article-title":"The significance of aberrant cytogenetic clones, emerging during treatment of chronic myelogenous leukemia with imatinib mesylate","volume":"92","author":"Symeonidis","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.cancergencyto.2008.12.013_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cancergencyto.2005.11.017","article-title":"Complex chromosomal rearrangements in patients with chronic myeloid leukemia","volume":"168","author":"Babicka","year":"2006","journal-title":"Cancer Genet Cytogenet"}],"container-title":["Cancer Genetics and Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460809000417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460809000417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T16:26:23Z","timestamp":1558283183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165460809000417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0165460809000417"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2008.12.013","relation":{},"ISSN":["0165-4608"],"issn-type":[{"value":"0165-4608","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}